anywhere  

Providing rapid, robust and reliable diagnosis and disease monitoring and analysis at the point of care: By the patient, for the patient.

The team

•  Dr  Nick  Brooks  

•  Dr  Ali  Salehi-­‐Reyhani  

•  Dr  Duncan  Casey  

•  David  Edwards  

Project  Management  

Scien0fic  /  Applica0on  Development  

Itera0ve  Product  Development  

Commercial  Development  

IP,  Legal  &  nego0a0on  advice  

Dr  Nick  Brooks  

Dr  Ali  Salehi-­‐Reyhani  

Dr  Duncan  Casey  

Imperial  Innova>ons    

David  Edwards  

The team Dr Nick Brooks

• Research lecturer at the Institute of Chemical Biology (ICB) at Imperial College.

• Successful background in high pressure instrument design, leading projects at international research centres.

Dr Ali Salehi-Reyhani • Post-doctoral researcher at the ICB with a PhD in microfluidic

engineering. • Specialises in development of lab-on-a-chip devices.

Dr Duncan Casey • Post doctoral-researcher at the ICB with a PhD in HPLC of

biological membranes. • Multidisciplinary researcher building optical tools for cell

biology. David Edwards

• Chemistry trained, with significant commercial experience developing product portfolios and routes to market.

• Leads financial and market modelling efforts for the project.

OneStart  funded  development  

•  The  OneStart  funding  will  be  used  to  develop  a  fully  func>onal  modular  β-­‐prototype  based  on  exis>ng  concept  designs  over  a  9  month  period.  

•  The  £100,000  will  allow  us  to  employ  an  engineering  based  researcher  for  9  months,  will  fund  specialist  manufacturing  consultancy  costs  and  allow  us  to  have  3  design  itera>ons  manufactured  by  external  workshops.    

•  This  prototype  will  form  a  plaNorm  for  applica>on  specific  op>misa>on  in  later  stages  of  the  project  and  will  facilitate  follow-­‐on  funding  applica>ons.  

���������

����� ����� ��� �'�� '(�&()% �,%!$�(�#���##$*�(�*��#�+

(���#$!$�-�($�"$#�($&�%�(��#('�+�(� ���&(���'��'�'� ����#���!�#���!

����'�$#'��#������#��'��#�����#(�*�!)��($����!(���&��%&$*���&'�

����&�����&$)%�$� ��%��&�$�����#!��!���$!" �&$"�(��

�#�*�&'�(-�$����"�&�����+�(���,%�&��#����#��!��(&$#��

�#��#��&�#�� #�#$���$(���#$!$�-���$"%)(�(�$#�!���$!$�-��#�

�)'�#�''���*�!$%"�#(�

�)&��$"%!�"�#(�&-���� �&$)#�'��$&"��#��,��!!�#(

�$)#��(�$#��$&�(���')���''�$��(���%&$%$'����#(�&%&�'��

��������������������#���

� ���#��� �!������� ���&"��$��#$"��'

� �!��$�"���!������������ "��&$�!��(&$#��'��

#�#$(���#$!$�-��$&����!(���&�

� �$����$ �� �(�(�'(���!���#�(��'��#��#�(+$& ���$!$�-

� �! �!�� ��������� ��$(���#$!$�-��$#')!(�#�-�

�#(&�%&�#�)&��!�"�#���"�#(��#� ��$#�#$(���

� ���������' $�'���!���� ��$�#�$&"�(��'

����#�!# �!�'�

� �)&�*�'�$#��'�($�)'��(�� �#��(�&( %&�.� ($�(&�#'�$&"�$)&

%�(�#(���'�#'�#��%!�(�$&"��#($�� �!�������������#

��%�������#������ "�##���

� ���'�+�!! �#��!��)'�($�'�� ���� ������� ($���&&-�(��

%&$�)�(�(�&$)���(���&��)!�($&-��%%&$*�!�%&$��''

!�������������#

��%�������������#$!�"

� ��&�!!�! '�#'�#��$��'�*�&�! ��

��$"�& �&'����

� ��#��()&�'����!��(&$#��'

� �#(��&�(���+�(����"$��!��%�$#�

*����������!�

� ��"%!���%%��$&���*����$)(%)(

High precision, wireless, automated home based foetal monitoring for pregnant mothers to monitor their babies themselves,

anytime and anywhere.

www.foetoh.com

Team

Dr. Michelle Fernandes • Co-founder and Leader Clinical Core (MBBS, DPhil. University of Oxford) • Expertise: Foetal neurodevelopment, foetal medicine, and antenatal monitoring • 1+ years of experience in clinical medicine, 6+ years of experience in research medicine • Current affiliation: FoetoH, the Nuffield Dept. of Obstetrics & Gynaecology, JR Hospital, Oxford

Dr. Ricardo Pachon • Co-founder and Leader Technology Core (MSc, DPhil. University of Oxford) • Expertise: pattern recognition automation, numerical mathematics • Co-author of Chebfun, a scientific computing software. • Current affiliation: FoetoH, CS Group AG

Medical Advisory Committee Dr. J. Hemelaar, the John Radcliffe Hospital, Oxford Dr. G. Menezes, Snehalaya Hospital, Solur, India

Prototype Advisory Committee Ning Zhang, , University of Oxford, UK Abhishek Appaji, BMSCE, Bangalore, India Luis Aranzeta, CTIN, Mexico Jomichael Porter, Stanford University, USA Riverlite Ltd., UK

Business Advisory Committee Allan Rodriguez, Dell Inc., USA Will Chadwick, TATA Interactive Systems, UK Simon Bennett, Simon Bennett Associates, UK Marks & Clerk LLP, UK

2013 2014 2015 2016 2017 2018

Key Milestone

Prototype Product

Dev. Pilot sales

UK UK

launch* European launch*

US launch*

No. Units 1 20 90 200 Revenue 250 5,000 22,500 50,000

Expenses 100 270 880 3,700 10,000 16,000

Profit (100) (270) (630) 1,300 12,500 34,000

Cashflow (100) (370) (1,000) 300 12,800 46,800

The Case to Onestart

£100,000 Completely facilitate Phase II: 1. The development of the beta prototype 2. Preliminary laboratory & clinical testing of the beta 3. CE marking 4. The full time involvement of the team in a dedicated FoetoH office 5. Initial conversations with MNOs &larger medical device manufacturers 6. Accelerate pilot sales to Q3 2014

Figures  in  ‘000s,  Currency  GBP,  *Associated  with  commercialization  partners.  Assumes  retailing  at  £250  per  unit;  cost  per  unit of £35.

   

HackeR  Biologics,  Cambridge,  UK  HackeR.biologics@gmail.com  

   

 

 Hackett Biologics has developed a proprietary technology that stabilises stem cells at room temperature, removing the consequences

associated with freezing

The  Team  

• Previously  assistant  professor  of  regenera>ve  medicine  at  Linkӧping  University  in  Sweden,  scien>st/strategy  lead  at  Pfizer  Neusen>s,  Director  of  Business  Development  for  Bodymetrics.    

• President  and  CSO  of  HackeR  Biologics  since  2009  and  currently  the  strategic  &  commercial  partnerships  execu>ve  at  the  Royal  Society  of  Chemistry  

• PhD  and  postdoctoral  research  in  regenera>ve  medicine  and  >ssue  engineering  

Dr.  Joanne  M.  HackeR,  Founder  and  CSO  

• Experienced  stem  cell  biologist  at  the  University  of  Cambridge,  Linkӧping  University  and  University  of  ORawa  

• Herchel  Smith  Research  Associate  –  University  of  Cambridge  • Consultant  at  HackeR  Biologics  since  2009  • PhD  and  postdoctoral  research  in  neural  stem  cell  differen>a>on  and  prolifera>on  

Dr.  Ryan  B.  MacDonald,  Project  Manager  and  Scien>fic  Advisor  

The  £100,000  investment…  

Will  be  used  to:    –  protect  intellectual  property  –  engage  advisors,  commercial  consultants  and  collaborators  

–  undertake  further  stability  and  characteriza>on  studies  –  perform  feasibility  studies  on  addi>onal  cell  lines    

•  generate  revenue  which  can  be  reinvested  to  secure  licensing  deals  with  major  companies    

–  provide  seed  funding  for  future  grant  applica>ons  (e.g.  TSB)  

Natalie  Cureton  1st  year  PhD  student  in  

Nanotechnology  sponsored  by  the  BBSRC  DTP  

BSc  Pharmaceu>cal  Science  (2012)  

Anna  King  2nd  year  PhD  student  in  

Nanotechnology  sponsored  by  the  NowNano  DTC  

MPhys  Physics  (2011)  Innova>on  and  

Commercialisa>on  of  research  (2012)  

Dr.  Lynda  Harris  BBSRC  David  Phillips  Research  Fellow    (2010-­‐2015)  PhD  (2003)  

BSc  Pathobiology  (1999)  

The  £100,000  prize  will:    

§     Give  us  the  financial  support  required  to  complete  full  toxicology  and  safety  studies  

§     Enable  us  to  purchase  instruments  to  assist  in  the  manufacture  of  larger  quan00es  of  LipoPep  

§     Allow  us  to  explore  delivery  of  different  therapeu0cs  

§     Provide  us  with  the  founda0on  required  to  take  LipoPep  through  Phase  I  and  Phase  II  clinical  trails    

MPDx  TECHNOLOGIES  

THE  MISSING  PIECE  –  Enabling  True  Point  of  Care  Diagnos4cs  

MPDx  INTERDISCIPLINARY  TEAM  

Maa  Wilkinson  MBA  Business  Development  Experienced  technical  sales  and  marke>ng  industry  professional  

Devaki  Bhaaa  PhD  Scien0fic  Director  10+  yrs  diagnos>cs  start-­‐up  experience  Mul>-­‐disciplinary  exper>se  (business  &  technical)  

Andy  Dixon  MSc  Chief  Engineer  Lab  automa>on  specialist  &  inventor  on  core  patents  

Liz  Nyeko  MBA  Finance  Officer  Background  in  investment  banking  focused  on  healthcare  

Prof  Judith  Hall  MD  OBE  Clinical  Lead,  Cardiff  Hospital  Cri>cal  care  consultant  with  30+  yrs  exper>se  in  diagnosis  and  early  interven>on  in  sepsis;  Able  to  influence  NHS  technology  adop>on  strategy        

Mark  Phillips  SVP  GSK  Diagnos0cs    Senior  execu>ve  with  25+  yrs  diagnos>cs  &  pharma  experience  Early-­‐stage  biotech  business  mentor  

Prof  Chris  Lowe  OBE  Director  of  Biotechnology,  University  of  Cambridge  35+  yrs  experience  in    healthcare  technology  commercialisa>on  ‘Most  entrepreneurial  scien>st  of  the  UK’  

Core  Team  

Advisory  Board  

USE  OF  ONESTART  £100K  

•  Genera0on  of  comprehensive  data  pack  comprising  key  applica0on-­‐

specific  test  results    

•  Significant  advances  in  next-­‐genera0on  prototype  development  

 

•  Recruitment  of  key  hires  (scien0st,  engineer)  to  enable  above    

Importantly,  OneStart  financing  will  enable  MPDx  to  leverage  significant  government  grants,  crea>ng  added  value  and  posi>oning  the  company  as  an  aRrac>ve  investment  opportunity.  

Picoto offers a comprehensive, portable newborn monitoring solution to bring a new global standard of care through unique sensors and intelligent data fusion algorithms.

Picoto is the brainchild of several University of Oxford researchers who specialize in data analytics, biotechnology innovation, and clinical medicine:

The Operational

team The

Technology team

The Medical

team

We are also supported by a stellar group of advisors from international organizations vested in the development of better clinical care and practice

Oliver Bent Mohammed Shahid Jon Daly Dr. Violeta Monasterio

Dr. Alexander Finlayson Jayson Marwaha

Sana Fathima

Elnaz Gederi Maxim Osipov

Starting with OneStart.

The One Start Prize money will be used to finish the final prototype and validation studies. The 100k

OneStart Prize

Final Prototype

Regulatory Approval

Validation Studies

Towards 1st Round

Seed Funding

Next  genera+on  purifica+on  for  today’s  and  tomorrow’s  biotherapeu+cs  –  reducing  

manufacturing  costs  by  25%  

Oliver Hardick, EngD Founder & CEO Current:   Postdoctoral  Fellow  at  UCL  in  Biochemical  Engineering,  a  recognised  world  expert  in  nanofibre  

purifica>on  and  original  inventor  of  FibroSelect  

Experience:   Director  property  company  (4  years);  Research  Engineer  –  STFC  (4  years);  Consultant  (intern)  

Academics:   EngD  (UCL);  BEng  1:1  (UCL);  -­‐  Sir  Derek  Roberts  Scholarship  (2005),  Jacobs  Engineering  Award  (2008),  Finalist  Material  Science  Sapphire  Prize  (2011),  BioProducts  Laboratory  Prize  (2012)  

Iwan Roberts, MEng, MRes Co-Founder & COO Current:   Final  year  doctoral  student  in  Biochemical  Engineering  (EngD)  

Experience:   IMS  Consul>ng  Group  (internship);  UK  Parliament  (adviser),  experience  in  running  technological  feasibility  studies  for  companies,  worked  with  Oliver  on  various  projects  over  the  last  7  years  

Academics:   MRes  Dis>nc>on  (UCL),  MEng  1:1  (Deans  list,  UCL),  completed  entrepreneurial  MBA  modules  at  London  Business  School  

Tom Haywood, CFA Co-founder & CFO Current:   Part-­‐>me  policy  adviser  for  the  CFA  Society  of  the  UK  

Experience:   Investment  Banking  (Deutsche  Bank  3  yrs);  Accoun>ng  (DeloiRe  1  yr)  

Academics:   CFA  Charterholder;  MSc  in  Biodiversity  Conserva>on  and  Management  (Oxford  University);  First  class  BA  Hons  Classics  (UCL)  

23

Spinout from the department of Biochemical Engineering

Team have been close friends for eight years

What  will  OneStart  mean  to  us?  

24

We plan to develop, test at scale and then license our technology £100k – matched with TSB SMART, will allow us to….

•  Design and build an industrial scale prototype •  Test prototype at UCL using industrial facilities •  Base a demo/development rig at the Stevenage BioScience Catalyst •  Cover costs for first feasibility study with end user

OneStart advice and support will help us to execute our plan

•  Network memberships will provide end user and licensee access •  Lab space can be used for prototype refinement and demonstrations •  Legal advice vital for licence model

OneStart would take Puridify to an investment inflection point •  Product proved in-house at relevant industrial scale •  Data will add value for future licensee negotiations

Pym  

An integrated platform for mobile diagnostics, bringing a laboratory to the phone in your hand

Pym  

James Flewellen Irwin Zaid Postdoctoral Researcher at University of Oxford

Junior Research Fellow at Christ Church, University of Oxford

Pym  and  OneStart  

£100k to: •  Develop a prototype device •  Optimise urinalysis software •  Rent cloud servers for processing and storage •  Design a mobile app

Superior  Low  Toxic  Nano-­‐delivery  Technology  for  Stem  Cell  Therapy  

STEM

Team  Name:  TECREA-­‐STEM  

Dr. Nidhin Raj Sales and Marketing Manager

Dr. Kantaraja Chindera, Business Development Director

Dr. Mittal Shah, Stem Cell Research Study Director

Mrs Klaudia Muniak, Laboratory Manager

Miss Fadhilah Kamaruzzaman, R&D Scientist I

Dr. Bhagyalakshmi Chengat Prakashbabu, R&D Scientist II

Tecrea-Stem Team

How  the  100  K  will  help  you  advance  your  idea  

We   already   have   in-­‐house   and   external   lab   based   evidence   demonstra0ng   that   our  technology  works  for  biomolecules  delivery  into  eukaryo0c  and  prokaryo0c  cells.  We  envision   that   with   further   op0misa0on   in   the   formula0ons,   our   technology   has   an  immense  poten0al  to  overcome  the  important  problem  of  biomolecule  delivery  in  the  stem  cell  sector,  which  will  enable  improved  research  and  transla0on  into  the  clinic.    • OneStart   funding  will   help  us   to  op0mise   condi0ons   for   improved  delivery  of  DNA,  RNA   and   protein   into   hard   to   transfect   primary   and   stem   cells.   This   would   help   to  improve   stem   cell   reprogramming   efficiency   and   advance   stem   cell   research   and  therapy.  

• The  outcome  will   be   superior,   non-­‐toxic  delivery   technology   specifically   formulated  for   primary   and   stem   cell   applica0ons.   This   will   strategically   posi0on   Tecrea-­‐stem  within  the  stem  cell  sector  and  allow  us  to  capture  a  substan0al  por0on  of  a  rapidly  growing,  high  margin  market.    

• Revenue  generated  from  product  sale  would  help  us  to  fund  other  applica0ons  of  our  technology,  including    in-­‐house  therapeu0c  stem  cell  reprogramming    R&D.  

• Success  with  Tecrea-­‐stem  will  enable  us  to  raise  further  funding  for  other  applica0ons  of  this  technology  in  clinics  (eg  for  an0microbial  delivery).